Real world eligibility for clinical trials in ES-SCLC

Stephen Liu shared on X/Twitter:

“We know that clinical trials represent an idealized population. Illustrated by report in JTOCRR: in Ontario, of 116 patients with SCLC, only 12.1% would have met eligibility for IMpower133 or CASPIAN trials that set the standard for 1L chemo-immunotherapy.”

Visit the article website.
Source: Stephen Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.